89bio, Inc/$ETNB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About 89bio, Inc
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Ticker
$ETNB
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
93
ISIN
US2825591033
Website
89bio, Inc Metrics
BasicAdvanced
$1.6B
-
-$3.30
1.29
-
Price and volume
Market cap
$1.6B
Beta
1.29
52-week high
$11.84
52-week low
$4.16
Average daily volume
1.9M
Financial strength
Current ratio
18.027
Quick ratio
16.861
Long term debt to equity
6.083
Total debt to equity
9.369
Interest coverage (TTM)
-70.83%
Profitability
EBITDA (TTM)
-403.25
Effective tax rate (TTM)
-0.19%
Management effectiveness
Return on assets (TTM)
-39.93%
Return on equity (TTM)
-69.30%
Valuation
Price to book
2.57
Price to tangible book (TTM)
2.57
Price to free cash flow (TTM)
-3.125
Free cash flow yield (TTM)
-32.00%
Free cash flow per share (TTM)
-340.82%
Growth
Earnings per share change (TTM)
63.41%
3-year earnings per share growth (CAGR)
-12.98%
What the Analysts think about 89bio, Inc
Analyst ratings (Buy, Hold, Sell) for 89bio, Inc stock.
Bulls say / Bears say
89bio successfully raised approximately $287.5 million in a public offering in January 2025, enhancing its financial position to support ongoing clinical trials and operations. (stocktitan.net)
Analysts have set a consensus price target of $27.56 for 89bio, indicating potential upside from current levels. (techdows.com)
Institutional investors, such as Woodline Partners LP, have significantly increased their holdings in 89bio, reflecting confidence in the company's prospects. (marketbeat.com)
In April 2025, 89bio reported a quarterly loss of $1.02 per share, missing analysts' expectations and raising concerns about its financial performance. (defenseworld.net)
Insider selling activity, such as the sale of 15,329 shares by insider Quoc Le-Nguyen in April 2025, may signal a lack of confidence in the company's near-term prospects. (defenseworld.net)
The biotechnology sector is highly competitive, and 89bio's lead product candidate, pegozafermin, faces potential challenges from existing and emerging therapies, which could impact its market share and revenue potential.
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
89bio, Inc Financial Performance
Revenues and expenses
89bio, Inc Earnings Performance
Company profitability
89bio, Inc News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for 89bio, Inc stock?
89bio, Inc (ETNB) has a market cap of $1.6B as of July 18, 2025.
What is the P/E ratio for 89bio, Inc stock?
The price to earnings (P/E) ratio for 89bio, Inc (ETNB) stock is 0 as of July 18, 2025.
Does 89bio, Inc stock pay dividends?
No, 89bio, Inc (ETNB) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next 89bio, Inc dividend payment date?
89bio, Inc (ETNB) stock does not pay dividends to its shareholders.
What is the beta indicator for 89bio, Inc?
89bio, Inc (ETNB) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.